In an effort to expand its cash runway beyond 12 months, Prime Medicines has signed a deal with Bristol Myers Squibb worth a ...
Johnson & Johnson linked Carvykti to a 45% reduction in risk of death and Darzalex to a 61% improvement in minimal residual ...
Six months after treatment with the radiopharmaceutical therapy, 77.8% of patients with meningioma were alive and had not ...
After the FDA declined to approve Lykos Therapeuticsâ MDMA-assisted therapy for post-traumatic stress disorder, companies are ...
Christopher Hart, a partner at the law firm Foley Hoag, noted that reproductive rights are currently fragmented across the ...
One upcoming decisionâon a perioperative PD-1 regimen for lung cancerâcomes as the FDA considers an overhaul of trial designs in this treatment setting.
Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinsonâs disease, ...
Pfizerâs sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in ...
In the Phase III REGENCY study, Gazyva elicited superior complete renal response rates in patients with lupus nephritis ...
Based on new safety signals, Pfizer on Wednesday announced that Oxbrytaâs overall benefit âno longer outweighs the riskâ in ...
If approved, the potential restrictions would impact Merckâs Keytruda and Bristol Myers Squibbâs Opdivo, which are marketed ...
Sen. Bernie Sandersâ aggressive targeting of Danish drugmaker Novo Nordiskâs Ozempic and Wegovy pricing, and not Eli Lillyâs ...